Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab - Chugai Pharmaceutical/Roche

Drug Profile

Tocilizumab - Chugai Pharmaceutical/Roche

Alternative Names: Actemra; ACTPen; Anti-IL-6 receptor antibody - Chugai; Anti-interleukin-6 receptor antibody - Chugai; Atlizumab; HPM-1; MRA; MRA - Chugai; MRA-SC; R-1569; RG-1569; rhPM-1; RO4877533; RoActemra

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical; Osaka University
  • Developer Assistance Publique Hopitaux de Paris; Biomedical Advanced Research and Development Authority; Charite - Universitatsmedizin Berlin; Chugai Pharmaceutical; Hospital for Special Surgery; JW Pharmaceutical; Roche; University Hospital Inselspital; University Hospital Tubingen; University of Bern; University of Pittsburgh
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug hypersensitivity; Giant lymph node hyperplasia; Vasculitis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections; COVID-19 pneumonia; Drug hypersensitivity; Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis; Systemic scleroderma
  • Registered Adult-onset Still's disease; Vasculitis
  • Phase III Osteoarthritis
  • Phase II Amyotrophic lateral sclerosis; Dermatomyositis; Familial Mediterranean fever; Polymyalgia rheumatica; Polymyositis; Pulmonary arterial hypertension; Schnitzler syndrome
  • Phase I/II Urogenital cancer
  • Phase I Pancreatic cancer
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Ankylosing spondylitis; Crohn's disease; Multiple myeloma; Systemic lupus erythematosus

Most Recent Events

  • 27 Mar 2024 Roche completes phase-I clinical trials in COVID-2019 infections (Adjunctive treatment, In infants, In children, In adolescents, In neonates) in US, Brazil, Croatia, France, Germany, Spain, Italy , Poland, South Africa, UK and Greece (IV) (NCT05164133)
  • 13 Sep 2023 Regulatory submission withdrawn for Systemic scleroderma in European Union (SC)
  • 09 May 2023 Registered for COVID-19 pneumonia in Taiwan (IV) before May 2023 (Chugai Pharmaceuticals pipeline, May 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top